Clinical Trial Update: A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of BAT4406F injection for Neuromyelitis Optica Spectrum Disorder is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• BAT4406F (BAT4406F)

Snippet

Sponsor: Bio-Thera Solutions | Conditions: Optic Neuromyelitis Spectrum Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING